IRIDEX

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IRIDEX reports Q1 revenue decline, explores strategic growth opportunities

IRIDEX faces challenges with longer sales cycles and margin pressure but maintains leadership in its core business areas.
Strategic discussions for potential transactions offer growth opportunities for the company and its stockholders.
Addressing revenue decline in retina products and improving cash position are key focus areas for future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRIDEX Corporation (IRIX) CEO Dave Bruce on Q4 2021 Results - Earnings Call Transcript

Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth

Iridex Announces Fourth Quarter and Full Year 2021 Financial Results

MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 34th Annual Roth Conference.

Iridex to Present at the 34th Annual Roth Conference

MOUNTAIN VIEW, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, March 10, 2022. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

Iridex to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021

IRIDEX Corporation (IRIX) CEO Dave Bruce on Q3 2021 Results - Earnings Call Transcript

Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance

Iridex Announces Third Quarter 2021 Financial Results

Iridex (IRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Iridex (IRIX) Soars 7.3%: Is Further Upside Left in the Stock?

An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021

Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Iridex (IRIX) Q3 Earnings Expected to Decline

AstroNova

Euroseas

FAT Brands

inTEST

Koss

Quest Resource Hld

Micro-cap stocks offer big growth potential, but not all opportunities are created equal. Each of these earns a Portfolio Grader “A” rating.

The Top 7 Micro-Cap Stocks to Buy Before 2022

MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 11, 2021. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

Iridex to Report Third Quarter 2021 Financial Results on November 11, 2021

MOUNTAIN VIEW, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming Lytham Partners Fall 2021 Investor Conference.

Iridex to Present at the Lytham Partners Fall 2021 Investor Conference

IRIDEX (IRIX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is IRIDEX (IRIX) Stock a Solid Choice Right Now?

Iridex Corporation (NASDAQ: IRIX) reported Q2 revenue of $13.4 million, the highest since 2007, +116% Y/Y, beating the consensus of $11.61 million. Cyclo G6 product family generated sales of $3.6 million, +70% Y/Y on 16,000 probes sold, up 103% Y/Y.

Iridex Stock Gains After Posting Highest Sales Since 2007

IRIDEX Corporation (IRIX) CEO Dave Bruce on Q2 2021 Results - Earnings Call Transcript

Iridex (IRIX) delivered earnings and revenue surprises of 43.75% and 15.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Iridex (IRIX) Reports Q2 Loss, Tops Revenue Estimates

Shares of Iridex (NASDAQ:IRIX) moved higher by 1.4% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 145.00% over the past year to $0.09, which beat the estimate of ($0.15).

Iridex: Q2 Earnings Insights

MOUNTAIN VIEW, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming H.C. Wainwright Ophthalmology Virtual Conference.

Iridex to Present at the 2021 H.C. Wainwright Ophthalmology Virtual Conference

Will Iridex (IRIX) Report Negative Q2 Earnings? What You Should Know

IRIX recently blew away analyst estimates for Q1 sales, with multiple tailwinds for continued success in 2021 and beyond.

Iridex: A Clear Vision For Success

IRIDEX Corporation (IRIX) CEO Dave Bruce on Q1 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021.

Iridex Announces First Quarter 2021 Financial Results

Earnings Preview: Iridex (IRIX) Q1 Earnings Expected to Decline

Iridex's (IRIX) fourth-quarter 2020 results benefit from strong product line-up and expanding market position.

News for IRIDEX Stock (IRIX)